Asana BioSciences announces dosing of first patient in Phase 1 trial of ASN004, a novel 5T4-Antibody-Drug-Conjugate

​ Lawrenceville, N.J. April --, 2022 – Asana BioSciences, LLC, a clinical stage biopharmaceutical company, today announced that the first patient has been dosed in a Phase 1 trial for ASN004, an antibody drug conjugate (ADC) targeting the 5T4 oncofetal antigen (trophoblast glycoprotein), that is expressed in a wide range of malignant tumors but shows very limited expression in normal tissues. Higher 5T4 expression is associated with worse clinical outcome in non-small cell lung, head and neck, gastric, pancreatic, colorectal, and ovarian cancers.

The release as fetched from its publisher. asanabio.com ↗